# Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

> **NCT03092375** · PHASE3 · COMPLETED · sponsor: **University of Florida** · enrollment: 177 (actual)

## Conditions studied

- Hepatitis C
- HCV

## Interventions

- **DRUG:** Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
- **DRUG:** Ribavirin 200Mg Tablet

## Key facts

- **NCT ID:** NCT03092375
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-20
- **Primary completion:** 2018-12-28
- **Final completion:** 2020-02-06
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2020-02-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03092375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03092375, "Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03092375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*